SMARCA4 and non-small cell lung carcinoma: Dagogo-Jack et al. (2020) observed SMARCA4 genomic alterations in 8% (117 of 1,422) and 12% (3,188 of 27,281) of NSCLCs in the institutional and Foundation Medicine datasets, respectively. Among 3416 NSCLC patients, approximately 25% had at least one SWI/SNF complex gene mutation, and of these patients, 9% harbored SMARCA4 mutations (Zhu et al., 2021). SMARCA4-deficient NSCLC (SMARCA4-dNSCLC) is a rare subtype of NSCLC that has unique clinicopathological features and a worse prognosis than SMARCA4-intact NSCLC (Bell et al., 2016; Liang et al., 2023).